HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Preprints, Working Papers, ...

Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model

Abstract : Abstract Impaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN-α starting one day pre-infection or one day post-infection limited weight loss and decreased viral lung titers. By contrast, intranasal administration of IFN-α starting at the onset of symptoms three days post-infection had no impact on the clinical course of SARS-CoV-2 infection. Our results provide evidence that early type I IFN treatments are beneficial, while late interventions are ineffective, although not associated with signs of enhanced disease. One Sentence Summary The timing of type I interferon treatment is a critical determinant of its efficacy against SARS-CoV-2 infection.
Complete list of metadata

https://hal-anses.archives-ouvertes.fr/anses-03387992
Contributor : Sophie Marchal-Mauer Connect in order to contact the contributor
Submitted on : Wednesday, October 20, 2021 - 10:34:31 AM
Last modification on : Tuesday, March 22, 2022 - 8:47:33 AM
Long-term archiving on: : Friday, January 21, 2022 - 7:28:16 PM

File

2021.02.09.430458v1.full.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Pierre Bessière, Marine Wasniewski, Evelyne Picard-Meyer, Alexandre Servat, Thomas Figueroa, et al.. Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. 2021. ⟨anses-03387992⟩

Share

Metrics

Record views

46

Files downloads

38